Search

Your search keyword '"Troger, Tobias"' showing total 23 results
Start Over Author "Troger, Tobias"
23 results on '"Troger, Tobias"'

1. Characteristics of Growth in Children With Classic Congenital Adrenal Hyperplasia due to 21-Hydroxylase Deficiency During Adrenarche and Beyond

Author

Troger, Tobias, Sommer, Grit; https://orcid.org/0000-0002-4205-7932, Lang-Muritano, Mariarosaria; https://orcid.org/0000-0002-0019-8657, Konrad, Daniel; https://orcid.org/0000-0001-9067-4356, Kuhlmann, Beatrice; https://orcid.org/0000-0002-3235-5717, Zumsteg, Urs, Flück, Christa E; https://orcid.org/0000-0002-4568-5504, Troger, Tobias, Sommer, Grit; https://orcid.org/0000-0002-4205-7932, Lang-Muritano, Mariarosaria; https://orcid.org/0000-0002-0019-8657, Konrad, Daniel; https://orcid.org/0000-0001-9067-4356, Kuhlmann, Beatrice; https://orcid.org/0000-0002-3235-5717, Zumsteg, Urs, and Flück, Christa E; https://orcid.org/0000-0002-4568-5504

Abstract

Context: Patients with classic congenital adrenal hyperplasia (CAH) often fail to achieve their full growth potential. Adrenarche may accelerate bone maturation and thereby result in decreased growth in CAH. Objective: To analyze the impact of growth during adrenarche on final height of adequately treated classic CAH patients. Design: Retrospective, multi-center study. Setting: Four academic pediatric endocrinology centers. Participants: Fourty-one patients with classical CAH, born between 1990 and 2012. Main outcome measures: We assessed skeletal maturation (bone age), growth velocity and (projected) adult height outcomes, and analyzed potential influencing factors, such as sex, genotype, and glucocorticoid therapy. Results: Patients with classic CAH were shorter than peers (-0.4SDS±0.8SD) and their parents (corrected final height -0.6SDS±1.0SD). Analysis of growth during adrenarche revealed two different growth patterns: patients with accelerating bone age (49%), and patients with non-accelerating bone age compared to chronological age (BA-CA). Patients with accelerating BA-CA were taller than the normal population during adrenarche years (p=0.001) and were predicted to achieve a lower adult height SDS (-0.9SDS, 95%CI -1.3;-0.5) than non-accelerating patients when assessed during adrenarche (0.2SDS, 95%CI -0.3;0.8). Final adult height was similarly reduced in both accelerating and non-accelerating BA-CA groups (-0.4SDS, 95%CI -0.9;0.1 vs -0.3SDS, 95%CI -0.8;0.1). Conclusions: Patients with and without significant bone age advancement, and thus differing height prediction during adrenarche, showed similar (predicted) final height when reassessed during pubertal years. Bone age alone should not be used during adrenarche as clinical marker for metabolic control in CAH treatment. Keywords: adrenarche; classic CAH; final height prediction; growth.

Published
2022

3. Issuer choice in Europe.

Author

Enriques, Luca and Troger, Tobias H.

Subjects
Securities law -- Evaluation
Published
2008

22. Remedies in Context: An Economics Perspective on Uniform Laws.

Author

Troger, Tobias and Friehe, Tim

Subjects
*INTERNATIONAL trade, *INTERNATIONAL agencies, *CONTRACTS (International law), *INTERNATIONAL law, *CONSUMER goods -- Law & legislation
Abstract

Since the middle of the 20th century, international organizations as well as private institutions have made efforts to harmonize the legal frameworks governing international trade-contracts. This paper looks into the remedies provided by uniform (Vienna Convention) or harmonized (European Directive on the Sale of Consumer Goods) sales laws in case a warranty is breached. Contrary to conventional economic analysis which mainly scrutinizes and compares individual remedies, it pays attention to the fact, that the international regulations - like many other sales laws - provide multiple remedies alternatively. It uses a game theoretical model to analyze the specific implications, the sequence of a multitude of remedies has and highlights where deviations from orthodox rationality assumptions (as a result of cultural, ethical etc. idiosyncracies) may hamper the desired effect of legal uniformity. ..PAT.-Unpublished Manuscript [ABSTRACT FROM AUTHOR]

Published
2008

23. Characteristics of Growth in Children With Classic Congenital Adrenal Hyperplasia due to 21-Hydroxylase Deficiency During Adrenarche and Beyond.

Author

Troger T, Sommer G, Lang-Muritano M, Konrad D, Kuhlmann B, Zumsteg U, and Flück CE

Subjects
Adolescent, Adrenal Hyperplasia, Congenital drug therapy, Adrenal Hyperplasia, Congenital genetics, Age Determination by Skeleton, Child, Dose-Response Relationship, Drug, Drug Monitoring methods, Female, Humans, Male, Retrospective Studies, Adrenal Hyperplasia, Congenital metabolism, Adrenarche metabolism, Body Height, Child Development, Glucocorticoids administration & dosage
Abstract

Context: Patients with classic congenital adrenal hyperplasia (CAH) often do not achieve their full growth potential. Adrenarche may accelerate bone maturation and thereby result in decreased growth in CAH., Objective: The study aimed to analyze the impact of growth during adrenarche on final height of adequately treated classic CAH patients., Methods: This retrospective, multicenter study (4 academic pediatric endocrinology centers) included 41 patients with classical CAH, born 1990-2012. We assessed skeletal maturation (bone age), growth velocity, and (projected) adult height outcomes, and analyzed potential influencing factors, such as sex, genotype, and glucocorticoid therapy., Results: Patients with classic CAH were shorter than peers (-0.4 SDS ± 0.8 SD) and their parents (corrected final height -0.6 SDS ± 1.0 SD). Analysis of growth during adrenarche revealed 2 different growth patterns: patients with accelerating bone age (49%), and patients with nonaccelerating bone age relative to chronological age (BA-CA). Patients with accelerating BA-CA were taller than the normal population during adrenarche years (P = 0.001) and were predicted to achieve lower adult height SDS (-0.9 SDS [95% CI, -1.3; -0.5]) than nonaccelerating patients when assessed during adrenarche (0.2 SDS [95% CI, -0.3; 0.8]). Final adult height was similarly reduced in both accelerating and nonaccelerating BA-CA groups (-0.4 SDS [95% CI, -0.9; 0.1] vs -0.3 SDS [95% CI, [-0.8; 0.1])., Conclusion: Patients with and without significant bone age advancement, and thus differing height prediction during adrenarche, showed similar (predicted) final height when reassessed during pubertal years. Bone age alone should not be used during adrenarche as clinical marker for metabolic control in CAH treatment., (© The Author(s) 2021. Published by Oxford University Press on behalf of the Endocrine Society.)

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results